Form 4: Clene Director Jacobovitz Granted Stock Options

Clene Inc. Director Shalom Jacobovitz was granted 2,816 stock options at an exercise price of $7.30 per share, vesting immediately.

Summary

• Shalom Jacobovitz, a Director of Clene Inc. (CLNN), acquired 2,816 stock options.
• The options were granted on November 13, 2025, under the Clene Inc. Amended 2020 Stock Plan.
• Each option has an exercise price of $7.30 per share.
• The options vest immediately upon grant.
• The expiration date for these options is November 12, 2035.
• Following this transaction, Shalom Jacobovitz beneficially owns 2,816 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued director involvement and alignment of interests, which is generally viewed favorably by investors. However, it's a routine compensation event, not a major catalyst.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the stock price increases.
• Immediate vesting of the options provides immediate equity exposure and incentive.

Risks

• The value of the stock options is subject to the future performance of Clene Inc.'s common stock; if the stock price does not exceed the exercise price of $7.30, the options may expire worthless.
• General market risks and company-specific operational risks could negatively impact the stock price.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports a past transaction.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and align leadership interests with shareholder value creation. The size of this grant is relatively small for a director, suggesting it may be part of a standard compensation package.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across publicly traded companies, including those in the biotech sector, to align interests.
• The immediate vesting of options is less common than phased vesting schedules, which typically tie vesting to continued service over several years. However, immediate vesting for director grants can occur, particularly for smaller grants or as part of an annual retainer.
• Without specific details on Clene Inc.'s peer group compensation policies, a direct comparison of the grant size (2,816 options) to industry benchmarks is difficult, but it appears to be a modest grant.

Corporate Governance

Related Party Transactions

• The grant of stock options to Shalom Jacobovitz, a Director of Clene Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Management/Directors: Provides an incentive for the director to contribute to the company's long-term success and share in potential upside.

Key Dates

Keywords

Clene Inc., CLNN, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Shalom Jacobovitz